Recombinant Mouse CD80/B7-1 Protein (Catalog#50446-M08H)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Mouse CD80/B7-1 (rM CD80/B7-1; Catalog#50446-M08H; Q00609-1; Met1-Lys245) and conjugated with APC under optimum conditions, the unreacted APC was removed.
Source
Monoclonal Rabbit IgG Clone #009
Purification
Protein A
Formulation
PBS solution containing 0.5% BSA and 0.09% sodium azide
Concentration
5 μl/Test, 0.1 mg/ml
Conjugate
APC
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Flow cytometric analysis of Mouse CD80 expression on LPS-stimulated BABL/c splenocytes. Cells were stained with APC-conjugated anti-Mouse CD80. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
Research Areas
Cancer Drug Targets
Tags
Cancer Immunotherapy
Co-inhibitory Immune Checkpoint Targets
Immune Checkpoint
Immune Checkpoint Detection: Antibodies
Immune Checkpoint Detection: ELISA Antibodies
Immune Checkpoint Detection: FCM Antibodies
Immune Checkpoint Detection: IHC Antibodies
Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets
Immunotherapy
Targeted Therapy
References
Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.
Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.
Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.